Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 20 entries
Sorted by: Best Match Show Resources per page
Insulin-like growth factor I (IGF-I) and regeneration of the sciatic nerve of the rat.

Restorative neurology and neuroscience

Kanje M, Skottner A, Sjöberg J.
PMID: 21551558
Restor Neurol Neurosci. 1990 Jan 01;1(3):211-5. doi: 10.3233/RNN-1990-13406.

We have found that insulin-like growth factor I (IGF-I) stimulates regeneration of the rat sciatic nerve. This paper reviews and adds some new data to our investigations on the effects of local administration of IGF-I to the sciatic nerve...

Cite
Kanje M, Skottner A, Sjöberg J. Insulin-like growth factor I (IGF-I) and regeneration of the sciatic nerve of the rat. Restor Neurol Neurosci. 1990;1(3):211-5doi: 10.3233/RNN-1990-13406.
Kanje, M., Skottner, A., & Sjöberg, J. (1990). Insulin-like growth factor I (IGF-I) and regeneration of the sciatic nerve of the rat. Restorative neurology and neuroscience, 1(3), 211-5. https://doi.org/10.3233/RNN-1990-13406
Kanje, M, et al. "Insulin-like growth factor I (IGF-I) and regeneration of the sciatic nerve of the rat." Restorative neurology and neuroscience vol. 1,3 (1990): 211-5. doi: https://doi.org/10.3233/RNN-1990-13406
Kanje M, Skottner A, Sjöberg J. Insulin-like growth factor I (IGF-I) and regeneration of the sciatic nerve of the rat. Restor Neurol Neurosci. 1990 Jan 01;1(3):211-5. doi: 10.3233/RNN-1990-13406. PMID: 21551558.
Copy Download .nbib Format: NLM
Ten years of progress--improved hysterectomy outcomes in Finland 1996-2006: a longitudinal observation study.

BMJ open

Mäkinen J, Brummer T, Jalkanen J, Heikkinen AM, Fraser J, Tomás E, Härkki P, Sjöberg J.
PMID: 24165027
BMJ Open. 2013 Oct 28;3(10):e003169. doi: 10.1136/bmjopen-2013-003169.

OBJECTIVES: To study the outcome of various hysterectomies in 2 years 1996 (N =10110) and 2006 (N=5279). The hypothesis was that the change in operative practices in 10 years has resulted in improvements.DESIGN: 2 prospective nationwide cohort evaluations with...

Cite
Mäkinen J, Brummer T, Jalkanen J, et al. Ten years of progress--improved hysterectomy outcomes in Finland 1996-2006: a longitudinal observation study. BMJ Open. 2013;3(10):e003169doi: 10.1136/bmjopen-2013-003169.
Mäkinen, J., Brummer, T., Jalkanen, J., Heikkinen, A. M., Fraser, J., Tomás, E., Härkki, P., & Sjöberg, J. (2013). Ten years of progress--improved hysterectomy outcomes in Finland 1996-2006: a longitudinal observation study. BMJ open, 3(10), e003169. https://doi.org/10.1136/bmjopen-2013-003169
Mäkinen, Juha, et al. "Ten years of progress--improved hysterectomy outcomes in Finland 1996-2006: a longitudinal observation study." BMJ open vol. 3,10 (2013): e003169. doi: https://doi.org/10.1136/bmjopen-2013-003169
Mäkinen J, Brummer T, Jalkanen J, Heikkinen AM, Fraser J, Tomás E, Härkki P, Sjöberg J. Ten years of progress--improved hysterectomy outcomes in Finland 1996-2006: a longitudinal observation study. BMJ Open. 2013 Oct 28;3(10):e003169. doi: 10.1136/bmjopen-2013-003169. PMID: 24165027; PMCID: PMC3816230.
Copy Download .nbib Format: NLM
Harmonisation of imaging dosimetry in clinical practice: practical approaches and guidance from the ESR EuroSafe Imaging initiative.

Insights into imaging

Vano E, Frija G, Stiller W, Efstathopoulos E, Granata C, Loose R, Paulo G, Pekarovic D, Sjöberg J, Donoso-Bach L.
PMID: 32232684
Insights Imaging. 2020 Mar 30;11(1):54. doi: 10.1186/s13244-020-00859-6.

The European Directive 2013/59/EURATOM requires member states of the European Union to ensure justification and optimisation of the radiological procedures and to include information on patient exposure as part of the report of the examinations. The EuroSafe Imaging campaign...

Cite
Vano E, Frija G, Stiller W, et al. Harmonisation of imaging dosimetry in clinical practice: practical approaches and guidance from the ESR EuroSafe Imaging initiative. Insights Imaging. 2020;11(1):54doi: 10.1186/s13244-020-00859-6.
Vano, E., Frija, G., Stiller, W., Efstathopoulos, E., Granata, C., Loose, R., Paulo, G., Pekarovic, D., Sjöberg, J., Donoso-Bach, L. (2020). Harmonisation of imaging dosimetry in clinical practice: practical approaches and guidance from the ESR EuroSafe Imaging initiative. Insights into imaging, 11(1), 54. https://doi.org/10.1186/s13244-020-00859-6
Vano, Eliseo, et al. "Harmonisation of imaging dosimetry in clinical practice: practical approaches and guidance from the ESR EuroSafe Imaging initiative." Insights into imaging vol. 11,1 (2020): 54. doi: https://doi.org/10.1186/s13244-020-00859-6
Vano E, Frija G, Stiller W, Efstathopoulos E, Granata C, Loose R, Paulo G, Pekarovic D, Sjöberg J, Donoso-Bach L. Harmonisation of imaging dosimetry in clinical practice: practical approaches and guidance from the ESR EuroSafe Imaging initiative. Insights Imaging. 2020 Mar 30;11(1):54. doi: 10.1186/s13244-020-00859-6. PMID: 32232684; PMCID: PMC7105556.
Copy Download .nbib Format: NLM
Hergen Spits-A legend at the top of his career.

Allergy

Mjösberg J, Roncarolo MG, Blom B.
PMID: 33751599
Allergy. 2021 Jun;76(6):1925-1928. doi: 10.1111/all.14788. Epub 2021 Mar 24.

No abstract available.

Cite
Mjösberg J, Roncarolo MG, Blom B. Hergen Spits-A legend at the top of his career. Allergy. 2021;76(6):1925-1928doi: 10.1111/all.14788.
Mjösberg, J., Roncarolo, M. G., & Blom, B. (2021). Hergen Spits-A legend at the top of his career. Allergy, 76(6), 1925-1928. https://doi.org/10.1111/all.14788
Mjösberg, Jenny, et al. "Hergen Spits-A legend at the top of his career." Allergy vol. 76,6 (2021): 1925-1928. doi: https://doi.org/10.1111/all.14788
Mjösberg J, Roncarolo MG, Blom B. Hergen Spits-A legend at the top of his career. Allergy. 2021 Jun;76(6):1925-1928. doi: 10.1111/all.14788. Epub 2021 Mar 24. PMID: 33751599.
Copy Download .nbib Format: NLM
Hip prosthetic loosening: A very personal review.

World journal of orthopedics

Mjöberg B.
PMID: 34631447
World J Orthop. 2021 Sep 18;12(9):629-639. doi: 10.5312/wjo.v12.i9.629. eCollection 2021 Sep 18.

Hip prosthetic loosening is often difficult to detect at an early stage, and there has been uncertainty for a long time as to when the loosening occurs and thus to the basic causes. By comparing different diagnostic methods, we...

Cite
Mjöberg B. Hip prosthetic loosening: A very personal review. World J Orthop. 2021;12(9):629-639doi: 10.5312/wjo.v12.i9.629.
Mjöberg, B. (2021). Hip prosthetic loosening: A very personal review. World journal of orthopedics, 12(9), 629-639. https://doi.org/10.5312/wjo.v12.i9.629
Mjöberg, Bengt. "Hip prosthetic loosening: A very personal review." World journal of orthopedics vol. 12,9 (2021): 629-639. doi: https://doi.org/10.5312/wjo.v12.i9.629
Mjöberg B. Hip prosthetic loosening: A very personal review. World J Orthop. 2021 Sep 18;12(9):629-639. doi: 10.5312/wjo.v12.i9.629. eCollection 2021 Sep 18. PMID: 34631447; PMCID: PMC8472441.
Copy Download .nbib Format: NLM
European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer.

ESMO open

Stanel SC, Sjöberg J, Salmonson T, Foggi P, Caleno M, Melchiorri D, Gravanis I, Tzogani K, Pignatti F.
PMID: 28761750
ESMO Open. 2017 May 02;2(2):e000190. doi: 10.1136/esmoopen-2017-000190. eCollection 2017.

On 1 February 2013, a marketing authorisation valid throughout the European Union was issued for aflibercept (Zaltrap) in combination with irinotecan/5-fluorouracil/folinic acid chemotherapy for the treatment of adults with metastatic colorectal cancer resistant to or progressive after an oxaliplatin-containing...

Cite
Stanel SC, Sjöberg J, Salmonson T, et al. European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer. ESMO Open. 2017;2(2):e000190doi: 10.1136/esmoopen-2017-000190.
Stanel, S. C., Sjöberg, J., Salmonson, T., Foggi, P., Caleno, M., Melchiorri, D., Gravanis, I., Tzogani, K., & Pignatti, F. (2017). European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer. ESMO open, 2(2), e000190. https://doi.org/10.1136/esmoopen-2017-000190
Stanel, Stefan Cristian, et al. "European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer." ESMO open vol. 2,2 (2017): e000190. doi: https://doi.org/10.1136/esmoopen-2017-000190
Stanel SC, Sjöberg J, Salmonson T, Foggi P, Caleno M, Melchiorri D, Gravanis I, Tzogani K, Pignatti F. European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer. ESMO Open. 2017 May 02;2(2):e000190. doi: 10.1136/esmoopen-2017-000190. eCollection 2017. PMID: 28761750; PMCID: PMC5519808.
Copy Download .nbib Format: NLM
Particle disease really does exist.

Acta orthopaedica

Pajarinen J, Gallo J, Takagi M, Goodman SB, Mjöberg B.
PMID: 29143557
Acta Orthop. 2018 Feb;89(1):133-136. doi: 10.1080/17453674.2017.1402463. Epub 2017 Nov 16.

No abstract available.

Cite
Pajarinen J, Gallo J, Takagi M, et al. Particle disease really does exist. Acta Orthop. 2017;89(1):133-136doi: 10.1080/17453674.2017.1402463.
Pajarinen, J., Gallo, J., Takagi, M., Goodman, S. B., & Mjöberg, B. (2018). Particle disease really does exist. Acta orthopaedica, 89(1), 133-136. https://doi.org/10.1080/17453674.2017.1402463
Pajarinen, Jukka, et al. "Particle disease really does exist." Acta orthopaedica vol. 89,1 (2018): 133-136. doi: https://doi.org/10.1080/17453674.2017.1402463
Pajarinen J, Gallo J, Takagi M, Goodman SB, Mjöberg B. Particle disease really does exist. Acta Orthop. 2018 Feb;89(1):133-136. doi: 10.1080/17453674.2017.1402463. Epub 2017 Nov 16. PMID: 29143557; PMCID: PMC5810823.
Copy Download .nbib Format: NLM
The Tonsil Lymphocyte Landscape in Pediatric Tonsil Hyperplasia and Obstructive Sleep Apnea.

Frontiers in immunology

Carrasco A, Sjölander I, Van Acker A, Dernstedt A, Fehrm J, Forsell M, Friberg D, Mjösberg J, Rao A.
PMID: 34745084
Front Immunol. 2021 Oct 22;12:674080. doi: 10.3389/fimmu.2021.674080. eCollection 2021.

Tonsil hyperplasia is the most common cause of pediatric obstructive sleep apnea (OSA). Despite the growing knowledge in tissue immunology of tonsils, the immunopathology driving tonsil hyperplasia and OSA remains unknown. Here we used multi-parametric flow cytometry to analyze...

Cite
Carrasco A, Sjölander I, Van Acker A, et al. The Tonsil Lymphocyte Landscape in Pediatric Tonsil Hyperplasia and Obstructive Sleep Apnea. Front Immunol. 2021;12:674080doi: 10.3389/fimmu.2021.674080.
Carrasco, A., Sjölander, I., Van Acker, A., Dernstedt, A., Fehrm, J., Forsell, M., Friberg, D., Mjösberg, J., & Rao, A. (2021). The Tonsil Lymphocyte Landscape in Pediatric Tonsil Hyperplasia and Obstructive Sleep Apnea. Frontiers in immunology, 12674080. https://doi.org/10.3389/fimmu.2021.674080
Carrasco, Anna, et al. "The Tonsil Lymphocyte Landscape in Pediatric Tonsil Hyperplasia and Obstructive Sleep Apnea." Frontiers in immunology vol. 12 (2021): 674080. doi: https://doi.org/10.3389/fimmu.2021.674080
Carrasco A, Sjölander I, Van Acker A, Dernstedt A, Fehrm J, Forsell M, Friberg D, Mjösberg J, Rao A. The Tonsil Lymphocyte Landscape in Pediatric Tonsil Hyperplasia and Obstructive Sleep Apnea. Front Immunol. 2021 Oct 22;12:674080. doi: 10.3389/fimmu.2021.674080. eCollection 2021. PMID: 34745084; PMCID: PMC8570126.
Copy Download .nbib Format: NLM
The aryl hydrocarbon receptor: a sentinel safeguarding the survival of immune cells in the gut.

Immunity

Spits H, Mjösberg J.
PMID: 22284414
Immunity. 2012 Jan 27;36(1):5-7. doi: 10.1016/j.immuni.2012.01.004.

Innate lymphoid cells (ILCs) regulate the epithelial barrier function and immunity in the gut. How ILC numbers are maintained is unknown. In this issue of Immunity, Qiu et al. (2012) report that the transcription factor aryl hydrocarbon receptor controls...

Cite
Spits H, Mjösberg J. The aryl hydrocarbon receptor: a sentinel safeguarding the survival of immune cells in the gut. Immunity. 2012;36(1):5-7doi: 10.1016/j.immuni.2012.01.004.
Spits, H., & Mjösberg, J. (2012). The aryl hydrocarbon receptor: a sentinel safeguarding the survival of immune cells in the gut. Immunity, 36(1), 5-7. https://doi.org/10.1016/j.immuni.2012.01.004
Spits, Hergen, and Mjösberg, Jenny. "The aryl hydrocarbon receptor: a sentinel safeguarding the survival of immune cells in the gut." Immunity vol. 36,1 (2012): 5-7. doi: https://doi.org/10.1016/j.immuni.2012.01.004
Spits H, Mjösberg J. The aryl hydrocarbon receptor: a sentinel safeguarding the survival of immune cells in the gut. Immunity. 2012 Jan 27;36(1):5-7. doi: 10.1016/j.immuni.2012.01.004. PMID: 22284414.
Copy Download .nbib Format: NLM
No Recirculation After Open Cancellous Bone Grafting. A Case Examined by Positron Emission Tomography.

Clinical positron imaging : official journal of the Institute for Clinical P.E.T

Emami A, Sundin A, Mjöberg B.
PMID: 10742681
Clin Positron Imaging. 2000 Jan;3(1):41-43. doi: 10.1016/s1095-0397(99)00111-9.

According to the Papineau technique, open autogenous cancellous bone grafting procedures were performed in tibial bone defects. Repeated positron emission tomography (PET) examinations with 2 tracers, [15O]water to assess blood flow and [18F]fluoride to assess bone metabolism, showed no...

Cite
Emami A, Sundin A, Mjöberg B. No Recirculation After Open Cancellous Bone Grafting. A Case Examined by Positron Emission Tomography. Clin Positron Imaging. 2000;3(1):41-43doi: 10.1016/s1095-0397(99)00111-9.
Emami, A., Sundin, A., & Mjöberg, B. (2000). No Recirculation After Open Cancellous Bone Grafting. A Case Examined by Positron Emission Tomography. Clinical positron imaging : official journal of the Institute for Clinical P.E.T, 3(1), 41-43. https://doi.org/10.1016/s1095-0397(99)00111-9
Emami, et al. "No Recirculation After Open Cancellous Bone Grafting. A Case Examined by Positron Emission Tomography." Clinical positron imaging : official journal of the Institute for Clinical P.E.T vol. 3,1 (2000): 41-43. doi: https://doi.org/10.1016/s1095-0397(99)00111-9
Emami A, Sundin A, Mjöberg B. No Recirculation After Open Cancellous Bone Grafting. A Case Examined by Positron Emission Tomography. Clin Positron Imaging. 2000 Jan;3(1):41-43. doi: 10.1016/s1095-0397(99)00111-9. PMID: 10742681.
Copy Download .nbib Format: NLM
EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.

The oncologist

Tzogani K, Hennik PV, Walsh I, De Graeff P, Folin A, Sjöberg J, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F.
PMID: 30037941
Oncologist. 2018 Jul;23(7):870. doi: 10.1634/theoncologist.2017-0301erratum.

No abstract available.

Cite
Tzogani K, Hennik PV, Walsh I, et al. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma. Oncologist. 2018;23(7):870doi: 10.1634/theoncologist.2017-0301erratum.
Tzogani, K., Hennik, P. V., Walsh, I., De Graeff, P., Folin, A., Sjöberg, J., Salmonson, T., Bergh, J., Laane, E., Ludwig, H., Gisselbrecht, C., & Pignatti, F. (2018). EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma. The oncologist, 23(7), 870. https://doi.org/10.1634/theoncologist.2017-0301erratum
Tzogani, Kyriaki, et al. "EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma." The oncologist vol. 23,7 (2018): 870. doi: https://doi.org/10.1634/theoncologist.2017-0301erratum
Tzogani K, Hennik PV, Walsh I, De Graeff P, Folin A, Sjöberg J, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma. Oncologist. 2018 Jul;23(7):870. doi: 10.1634/theoncologist.2017-0301erratum. PMID: 30037941; PMCID: PMC6058342.
Copy Download .nbib Format: NLM
Innate lymphoid cell composition associates with COVID-19 disease severity.

Clinical & translational immunology

García M, Kokkinou E, Carrasco García A, Parrot T, Palma Medina LM, Maleki KT, Christ W, Varnaitė R, Filipovic I, Ljunggren HG, Björkström NK, Folkesson E, Rooyackers O, Eriksson LI, Sönnerborg A, Aleman S, Strålin K, Gredmark-Russ S, Klingström J, Mjösberg J.
PMID: 33343897
Clin Transl Immunology. 2020 Dec 14;9(12):e1224. doi: 10.1002/cti2.1224. eCollection 2020.

OBJECTIVES: The role of innate lymphoid cells (ILCs) in coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is unknown. Understanding the immune response in COVID-19 could contribute to unravel the pathogenesis and identification of...

Cite
García M, Kokkinou E, Carrasco García A, et al. Innate lymphoid cell composition associates with COVID-19 disease severity. Clin Transl Immunology. 2020;9(12):e1224doi: 10.1002/cti2.1224.
García, M., Kokkinou, E., Carrasco García, A., Parrot, T., Palma Medina, L. M., Maleki, K. T., Christ, W., Varnaitė, R., Filipovic, I., Ljunggren, H. G., Björkström, N. K., Folkesson, E., Rooyackers, O., Eriksson, L. I., Sönnerborg, A., Aleman, S., Strålin, K., Gredmark-Russ, S., Klingström, J., Mjösberg, J. (2020). Innate lymphoid cell composition associates with COVID-19 disease severity. Clinical & translational immunology, 9(12), e1224. https://doi.org/10.1002/cti2.1224
García, Marina, et al. "Innate lymphoid cell composition associates with COVID-19 disease severity." Clinical & translational immunology vol. 9,12 (2020): e1224. doi: https://doi.org/10.1002/cti2.1224
García M, Kokkinou E, Carrasco García A, Parrot T, Palma Medina LM, Maleki KT, Christ W, Varnaitė R, Filipovic I, Ljunggren HG, Björkström NK, Folkesson E, Rooyackers O, Eriksson LI, Sönnerborg A, Aleman S, Strålin K, Gredmark-Russ S, Klingström J, Mjösberg J. Innate lymphoid cell composition associates with COVID-19 disease severity. Clin Transl Immunology. 2020 Dec 14;9(12):e1224. doi: 10.1002/cti2.1224. eCollection 2020. PMID: 33343897; PMCID: PMC7734472.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 20 entries